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Aims Heart failure (HF) treatment guided by physicians with access to real-time pressure measurement from a wireless
implantable pulmonary artery pressure (PAP) sensor (CardioMEMS), has previously been shown to reduce HF-related
hospital admissions in the CHAMPION trial. However, uncertainty remains regarding the value of CardioMEMS in
European health systems where healthcare costs are significantly lower than in the USA.
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Methods
and results
A Markov model was developed to estimate the cost-effectiveness of PAP-guided treatment of HF using the
CardioMEMS™ HF system compared with usual care. Cost-effectiveness was measured as the incremental cost
per quality-adjusted life year (QALY) gained. In the base case analysis over a time horizon of 10 years, PAP-guided
HF therapy increased cost compared with usual care by £10 916 (€14 030). QALYs per patient for usual care
and PAP-guided patients were 2.57 and 3.14, respectively, reflecting an increase of 0.57 QALYs with PAP-guided
treatment. The resultant incremental cost-effectiveness ratio (ICER) is £19 274 (€24 772) per QALY gained. The
base case analysis did not include staff time, due to a lack of data concerning this variable. Running the model with
estimated staff time included resulted in an increased ICER of between £22 342 and £25 464 per QALY gained
(€28 709–32 721).
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Conclusion The analysis indicates that integrating wireless PAP monitoring into the management of UK HF patients is likely to
be a cost-effective addition to the HF treatment pathway for appropriate patients.
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Introduction
In Europe, between 1% and 2% of the population have heart failure
(HF).1 The syndrome is associated with reduced life expectancy2
and an impaired quality of life.3 In the UK, there were 160 000
hospitalizations for HF in 2013/14,4 with an in-hospital mortal-
ity of 9.5% and a 1-year mortality risk of 27%.5 One estimate
from England’s National Institute for Health and Care Excel-
lence (NICE) suggests that the National Health Service (NHS)
spends £2.3 billion on HF (∼2% of its total budget), with 70% of
this expenditure due to hospitalization.6,7 The situation is similar
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. in many European countries.8 The primary symptom leading to
hospitalization for worsening HF is dyspnoea, related to fluid
retention and/or fluid redistribution, both of which are asso-
ciated with an increase in pulmonary artery (PA) pressures
(PAPs).9–12
A novel implantable haemodynamic sensor (CardioMEMS™ HF
system, St. Jude Medical Inc., Atlanta, GA, USA) has been developed
to provide physicians with remote real-time pressure measure-
ments from the pulmonary artery. In a randomized controlled trial
(RCT) of 550 NYHA class III HF patients with a previous HF hos-
pitalization enrolled at 64 US hospitals, doctors that used these
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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pressure measurements to guide their patients’ medical therapy
(treatment group) achieved a 33% reduction in HF-related hospital-
izations over an average study duration of 15 months13 compared
with the control arm who had the device implanted but where the
data were not used to guide management. The CardioMEMS sen-
sor has been approved for use in the USA by the Food and Drug
Administration (FDA), and in June 2016 the Heart Failure Asso-
ciation of the European Society of Cardiology (ESC) included the
system in the ESC guidelines for the diagnosis and treatment of
acute and chronic HF, indicating that the device may be considered
for monitoring symptomatic patients with a previous HF hospital-
izsation in order to reduce the risk of recurrent hospitalization
(class IIb recommendation, level of evidence B).14 Unlike other
implantable devices, the CardioMEMS pressure sensor does not
require a battery so can therefore, in theory, continue to function
indefinitely.
Modelling can be used to estimate the cost-effectiveness of Car-
dioMEMS by comparing its outcomes and costs with those of
usual care. If these outcomes are estimated as quality-adjusted
life years (QALYs), then the incremental cost-effectiveness ratio
(ICER), or cost per QALY gained, can be calculated as the dif-
ference in costs divided by the difference in QALYs. This can
aid decision-makers in determining whether a new intervention
is ‘value for money’ and should be funded or reimbursed. In
England, NICE typically recommends in favour of funding inter-
ventions with an ICER< £20 000/QALY, but requires consider-
able clinical benefit to recommend funding interventions between
£20 000 and £30 000/QALY, and typically recommends against
funding interventions with an ICER> £30 000/QALY. The aim
of this study is to estimate the likely incremental cost per
QALY of CardioMEMS compared with usual care, from a Euro-
pean perspective, so as to determine if this technology is likely
to be recommended according to typical NICE thresholds for
cost-effectiveness.
Methods
Scope of the model
A Markov model was developed in TreeAge 2015 (TreeAge Pro
2015, R1.0. TreeAge Software, Williamstown, MA, USA) to esti-
mate the cost-effectiveness of PAP-guided treatment of HF using the
CardioMEMS implantable pressure sensor compared with usual care
strategies. The model was applied to a hypothetical population of
20 000 patients with HF.
The clinical effectiveness of PAP-guided treatment was derived from
the pivotal RCT15 on US patients which showed a significant decrease
in hospitalizations related to HF, no effect on non-HF hospitalizations,
and a trend towards mortality benefit. Costs estimated in the model
included costs of the implantation procedure including the device and
related complications, costs of HF-related hospitalizations, and costs
of standard care.
Cost-effectiveness results were estimated as incremental cost per
QALY gained, using mean values of 1000 probabilistic sensitivity analy-
sis (PSA) runs, with each PSA run using different estimates for the risks,
hazard ratios (HRs), costs, and utilities to capture the uncertainty in
these input parameters. In effect, the computer simulation runs each of ..
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Figure 1 State transition diagram. The Markov model has two
health states, stable heart failure (HF) and death. There is a
monthly transition probability of moving from stable HF to dead
state. Hospitalization is modelled as an event; there is a monthly
risk of patients being hospitalized, which is used to estimate
the costs/quality-adjusted life years. The patients are assumed to
revert back to stable HF after hospitalization.
these 1000 sets of sampled values for each modelled patient (20 000);
the base case results below are the mean values of these 20 million
(20 000×1000) simulations.
Model structure
The Markov model considered two health states: ‘stable heart failure’
and ‘dead’ (Figure 1). The patients were assigned a monthly probability
of death based on their age and whether they had the intervention.
Each month in the model, the patients whowere alive were at risk of HF
hospitalization or dying. HF hospitalization was not a health state but
rather an event which patients might experience, an event which had
costs associated with it. Patients who experienced HF hospitalization
would then transition back to alive or dead at the end of that monthly
cycle. Each patient then accrued QALYs and healthcare costs according
to their hospitalization and treatment status. The model used a 10-year
time horizon; the costs and QALYs were estimated using a healthcare
payer perspective and discounted at an annual discount rate of 3.5%. It
was assumed that patients entering the model were aged 70, the typical
age of HF patients who are remotely monitored in the developed
world.16
Baseline mortality and hospitalization
risk
The data for baseline risk of death were based on previous work by
Griffiths et al. (in their 2014 model estimating cost-effectiveness of
ivabradine for the treatment of HF).17 They estimated mortality rates
based on the CARE-HF trial, an RCT conducted on NYHA class III and
IV HF patients with a prior hospitalization event and adjusted using UK
interim life tables and increases with age in 5-yearly steps as shown in
Table 1.
The baseline risk of hospitalization was based on a meta-analysis
of 21 HF telemonitoring studies of 5715 patients, median age 70.7
(range 45–78 years), with 54% of patients in NYHA class III.16 The
average number of monthly HF-related hospitalizations for patients in
usual care is shown in Table 1.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Summary of variables
Variable group Variable
description
Distribution
used in PSA
Mean value Source
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Model settings Age of patients entering the model 70
Model time horizon 10
Costs Cost of an implant complication Fixed £1090 UK reference costs
Total cost of implant procedure including
cost of equipment and device
Fixed £12 000 Estimate
Monthly cost to deliver medical care fixed £36 Griffiths et al.17
Cost of a HF hospitalization normal £2038 UK reference costs
Hourly rate for Band 5 nurse Not run in base case
Sensitivity analysis only
£36 PSSRU21
Hazard ratio Hazard ratio reduction in HF hospitalization
treatment cohort
Log normal 0.67 Abraham et al.37
Hazard ratio reduction in mortality
treatment cohort
Log normal 0.8 Abraham et al.37
Risk of implant complication Fixed 0.0272 CHAMPION trial data
Risks Monthly risk of HF hospitalization Beta 0.035 Klersy et al.16
Mortality risk age 45–50 Beta 0.00125 Griffiths et al.17
Age-related mortality
risk
Mortality risk age 50–55 Beta 0.00197 Griffiths et al.17
Mortality risk age 55–60 Beta 0.00296 Griffiths et al.17
Mortality risk age 60–65 Beta 0.0046 Griffiths et al.17
Mortality risk age 65–70 Beta 0.00698 Griffiths et al.17
Mortality risk age 70–75 Beta 0.01044 Griffiths et al.17
Mortality risk age 75–80 Beta 0.01566 Griffiths et al.17
Mortality risk age 80–85 Beta 0.02136 Griffiths et al.17
Mortality risk age 85–90 Beta 0.02301 Griffiths et al.17
Mortality risk age 90+ Beta 0.01864 Griffiths et al.17
Utility values for
CardioMEMS
patients
Trial utility at 1 month for treatment group Normal 0.688 CHAMPION trial data
Trial utility at 3 months for treatment group Normal 0.646 CHAMPION trial data
Trial utility at 6 months for treatment group Normal 0.617 CHAMPION trial data
Trial utility at 12 months for treatment
group
Normal 0.653 CHAMPION trial data
Utility values for usual
care patients
Trial utility at 1 month for usual care Normal 0.645 CHAMPION trial data
Trial utility at 3 months for usual care Normal 0.569 CHAMPION trial data
Trial utility at 6 months for usual care Normal 0.566 CHAMPION trial data
Trial utility at 12 months for usual care Normal 0.547 CHAMPION trial data
Utility value for stable
HF patients
Utility for patients with chronic HF Fixed 0.57 Matza et al.19
Disutility for
hospitalization
Disutility for HF hospitalization after 5 years Triangular −0.1 Klersy et al.16
HF, heart failure; PSA, probabilistic sensitivity analysis; PSSRU, Personal Social Services Research Unit.
Treatment effect
Hazard ratios associated with mortality and HF hospitalizations for
CardioMEMS were taken from the CHAMPION trial, and were applied
to the baseline monthly risk of mortality and HF hospitalization
described above. The HRs used in the model are presented in Table 1.
Due to the uncertainty regarding the mortality effect at this time, it
was decided not to model the mortality effect beyond 5 years, after
which the mortality risk is assumed to be the same for both cohorts
within the model.
Prior to entering the Markov model, a small proportion (2.7%) of
patients in the CardioMEMS cohort were assumed to experience an
implant-related complication, based on data from the CHAMPION
trial.15 ..
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. Health-related quality of life
Health-related quality of life (or utilities) for the patients was based
on the European Quality of Life (EuroQoL) Five Dimensions, three
level questionnaire (EQ-5D-3L) data, collected from the patients within
the CHAMPION trial at 1, 3, 6, and 12 months. Mean utility values
calculated over time for both cohorts (i.e. CardioMEMS and usual care)
are presented in Table 1.
After 12 months, utility values were assumed to decrease at a
rate of 0.008 per year, based on a longitudinal study in a popu-
lation of Swedish HF patients.18 This assumption was also used in
the recent Novartis submission to NICE for sacubitril–valsartan.7
Trial utilities were modelled out to 5 years, after which a utility
of 0.57 was applied for chronic HF based on a recent study in
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the UK,19 which was again decreased at a rate of 0.008 per year
thereafter.
After 5 years, when trial utilities ceased to be applied and in order
to avoid double counting, a disutility for each HF hospitalization of
–0.1 is applied to reflect the impact of hospitalizations on quality
of life. This is similar to the disutility applied to hospitalizations
from a previous cost-utility analysis for HF technologies,20 Griffiths
et al.,17 and, more recently, the Novartis submission to NICE for single
technology appraisal of sacubitril–valsartan.7
Costs
As of autumn 2016, the cost of the device has not been released by
the manufacturer as devices are not commercially available in Europe
outside of use in clinical trials, and an implant procedure code is not
available from the NHS. However, the authors have in this case assumed
that the total cost of device acquisition and implant will be £12 000,
based on the direct currency conversion from the average US MS-DRG
payment (DRG 264 accompanied by the ICD-9-CM procedure code
of 38.26: insertion of implantable pressure sensor without lead for
intracardiac or great vessel haemodynamic monitoring), currently set
at US$17 750.
The cost of an implant complication is estimated as £1090, using
a weighted average of the eight complications in the CHAMPION
trial mapped to NHS reference costs.21 The cost of standard HF care
(excluding hospitalizations) is £36.31 per month based on previous
estimates,17 and is applied to stable HF patients in both cohorts. The
cost of HF hospitalization is estimated from NHS reference costs as
£2038, calculated as a weighted average of HF admissions.
Sensitivity analysis
One-way sensitivity analysis was performed on the following parame-
ters: HR for mortality reduction (0.55 to 1) from the lower bound of
the 95% confidence interval (CI) fromCHAMPION to 1 being no effect
on mortality; HR for HF hospitalization (0.55 to 0.8) across the 95% CI
from CHAMPION; cost of HF hospitalization (£1067 to £3884), from
the lowest to highest costs of HF hospitalization in the NHS reference
costs; and cost of implant procedure (±25%, £9000–£15 000).
A subgroup analysis of 119 patients in the CHAMPION trial with
preserved EF (>40%) revealed that the treatment effect could be
greater in these patients, reducing the hospitalization rate by 50%. This
scenario was tested in the model.
The costs of HF hospitalization, implant complications, and monthly
cost of treatment were acquired from several other European coun-
tries and the cohort model run using these inputs to simulate
cost-effectiveness in other countries.
Probabilistic sensitivity analysis was performed using 1000 runs
employing different estimates for the risks, HRs, costs, and utilities.
Scenario analysis, including staff costs
A scenario analysis was also performed including the time spent on
monitoring patients by a nurse (23–70 min per month). The lower
bound of this range is from data collected by L.K. on CardioMEMS
patients at his centre, and the upper bound is from a previous
telemonitoring study using different technology.22 Physician time was
included at 7 min per month, again from early real-world data collected
by L.K. at the University of California, San Francisco, Medical Centre.
The costs for the time spent by nurses monitoring CardioMEMS ..
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.. patients remotely is based on an hourly rate of £36 for a Band 5 nurse,
and for doctors £105/h for a medical consultant.21
Results
Base case analysis
In the base case analysis over a time horizon of 10 years,
PAP-guided HF therapy increased cost compared with usual care
by £10 916 (i.e. from £6189 in usual care to £17 104 in PAP-guided
HF therapy).
The model estimated a mean survival of 4.79 years for patients
being treated with usual care practices and 5.17 years for patients
with treatment guided by PAP monitoring, an increase of 0.38 years
(Figure 2).
The QALYs per patient for usual care and PAP-guided patients
were 2.57 and 3.14, respectively, reflecting an increase of 0.57
QALYs with PAP-guided treatment. The resultant ICER, the ratio
between incremental costs and the QALYs, is estimated at £19
274/QALY.
Probabilistic sensitivity analysis
The results of the PSA displayed on a scatterplot (ellipse indicates
95% CI) show a tight cluster of results in the north-east quadrant.
A line indicating a willingness to pay (WTP) threshold of an
ICER of £20 000 has been drawn for reference (Figure 3); this
line represents the WTP threshold below which NICE typically
recommends a new treatment be made available to NHS patients.
Almost all of the points on the scatterplot are underneath the line,
as the probability of PAP being cost-effective at a WTP threshold
of £20 000/QALY is 97.6%.
Sensitivity analysis (Figure 4)
Sensitivity analyses performed do not substantially change the
conclusions, as shown in Figure 3. Decreasing the mortality HR
of PAP to 0.55 (from a base value of 0.8) resulted in an ICER
of £11 205/QALY. This is due to a much greater difference
in the expected QALYs between the PAP arm and the usual
care arm when a lower HR was used. Similarly, increasing the
mortality HR of PAP to 1 resulted in an ICER of £31 119/QALY.
When the cost of the implant procedure was decreased to £9000
(from a base value of £12 000), the ICER went down to £14
106/QALY. Similarly, using a higher cost of implant procedure
(£15 000) resulted in a higher ICER (£24 811/QALY). Decreasing
the HF hospitalization HR of PAP to 0.55 (from a base value
of 0.67) resulted in a lower ICER of £18 661/QALY. Again, this
is due to a higher difference in the expected QALYs between
the PAP arm and the usual care arm when a lower HR was
used. Similarly, increasing the HF hospitalization HR of PAP to 0.8
resulted in a higher ICER of £21 191/QALY. When the cost of
HF hospitalization was decreased to £1067 (from a base value
of £2038), the ICER increased to £20 558/QALY. This is due to
lower savings between the PAP arm and the usual care arm due to
reduced HF hospitalizations when lower HF hospitalization costs
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Survival curve showing the number of patients alive in the model over time. At 5 years, when the mortality effect from CHAMPION
is removed from the model, the mortality rate increases. PAP, pulmonary artery pressure.
Figure 3 Cost-effectiveness scatter plot. Each of the dots on the scatter plot is one of 1000 mean cost and utility results of 20 000 model
runs each with different input values sampled from the input distributions. PAP, pulmonary artery pressure; WTP, willingness to pay. The
WTP= £20 000/QALY (quality-adjusted life year) is the typically accepted NICE (National Institute for Health and Care Excellence) threshold.
Almost all of the samples (97.6%) fall under the WTP threshold, suggesting that CardioMEMS has a 97.6% probability of being cost-effective at
that threshold.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 One-way sensitivity analysis. The results of the sensitivity analysis can be compared in this tornado diagram; a larger bar indicates a
greater impact on the incremental cost-effectiveness ratio (ICER) or, in the case of mortality, indicates a wide range of uncertainty. The dotted
line indicates the base case ICER. In the case of increased heart failure (HF) hospitalization costs the ICER is lower. HR, hazard ratio.
Table 2 Comparison of costs and cost-effectiveness between countries
UK The Netherlands Belgium Italy Germany
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inputs
Cost of an implant complication £1090 €2390 €1630 €3481 €2668
Cost of implant (includes device cost) £12 000 €15 000 €15 000 €15 000 €15 000
Monthly cost to deliver medical care £36 €99 €27 €148 €231
Cost of one hospital admission for HF £2038 €4545 €2802 €4500 €4398
Outputs
Modelled cost of usual care £6189 €14 831 €7187 €17 556 €22 121
Modelled cost of PAP-guided therapy £17 104 €27 472 €20 582 €30 483 €35 468
Incremental cost £10 916 €12 641 €13 395 €12 926 €13 347
ICER £19 274 €22 555 €23 899 € 23 064 €23 814
HF, heart failure; ICER, incremental cost-effectiveness ratio; PAP, pulmonary artery pressure.
were used. Similarly, the ICER decreased to £17 370/QALY when
the cost of hospitalization was increased to £3884.
When the model was run using the increased treatment effect
found in the preserved EF patients, costs for the treatment group
were reduced to £16 518 and the resultant ICER was £18 169.
Comparison of model results in selected
European countries
The model outputs were tested with cost inputs from four other
European countries, The Netherlands, Belgium, Italy, and Ger-
many. Comparative cost inputs and model outputs can be seen
in Table 2. It should be noted that the clinical parameters were .
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.. unchanged. These analyses suggest that CardioMEMS is likely to be
cost-effective in the countries selected.
Scenario analysis, including staff costs
Scenario analysis performed, including the costs for nurses and
doctors managing the data from the pressure monitors, increased
the ICERs. When it was assumed that the time spent by a
nurse monitoring each PAP patient is 23 min/month and that
doctors spent 7 min/month per patient, the ICER increased to
£22 342/ QALY. If the time needed for nurses to manage these
patients was assumed to be 70 min/month, the ICER increased to
£25 464/QALY.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Discussion
The results of our cost-utility analysis suggest that the
CardioMEMS™ HF system could provide cost-effective bene-
fits to HF patients in the UK: the base case ICER of £19 274/QALY
is below the thresholds of £20 000–£30 000 per QALY used
by NICE.
The CardioMEMS device differs from previous telemonitoring
technologies in that it is the first system to provide real-time
remote monitoring of PAP, with the goal of maintaining this
pressure within a therapeutic range by adjusting medications in
response to pressure trends. Previous remote monitoring sys-
tems have used non-invasive measurements such as weight, heart
rate, and blood pressure communicated to physicians via tele-
phone or data links, or data from cardiac implantable electronic
devices implanted for therapeutic reasons (such as an implantable
cardioverter defibrillator or CRT device).
Meta-analysis of several small studies of non-invasive remote
monitoring suggested that such approaches may reduce HF
hospitalizations and perhaps mortality,23 but larger randomized
trials have been neutral.24–26 A UK cost-effectiveness analysis
used modelling to compare structured telephone support where
patients spoke to a human operator (usually a HF nurse), struc-
tured telephone support delivered by an automated machine,
and remote monitoring of non-invasive measurements. Remote
monitoring was superior in terms of cost-utility to either of
the structured telephone support approaches, with an ICER of
£9522/QALY gained over a lifetime horizon.20,27
A recent meta-analysis of remote monitoring of devices
implanted for therapeutic reasons has suggested no change in
mortality but a marked reduction in planned hospital visits, at
the expense of an increase in unplanned hospital and emergency
room visits.16 The CardioMEMS system directly measures PAP,
and may provide an earlier indicator of decompensation,28 in addi-
tion targeting the haemodynamic congestion, rather than clinical
congestion, targeted by traditional remote monitoring solutions.
Besides being a new therapeutic target with drug therapies titrated
to maintain PAP in a more normal range, the indicator showed
improved efficacy under randomized conditions which is probaby
due to the physical parameter being monitored, i.e. PAP, being
better able to detect early signs of acute decompensation. Fur-
thermore, the CHAMPION trial only included patients who were
at least moderately symptomatic (NYHA class III), and perhaps
with a greater potential to obtain benefit in terms of reduced
hospitalization and improved quality of life than the other studies
which tended also to recruit patients with milder symptoms.
Others have estimated the likely cost-effectiveness of the
CardioMEMS device in the American healthcare system. Sandhu
and colleagues estimated an ICER of US$71 462 per QALY
gained.29 The key differences, apart from the different costs of
hospitalization in the different healthcare systems, are the assump-
tions relating to utilities. Sandhu et al. used the results of the
disease-specific Minnesota Living with Heart Failure (MLWHF)
assessments in the CHAMPION trial, converted to EQ-5D utilities
using an algorithm, whereas the model presented here uses utility
values derived directly from the EQ-5D assessments collected in ..
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.. the CHAMPION trial because data quality (in terms of number
of questionnaires completed) was much better for EQ-5D. Both
models extend the utility effects beyond the trial period, but in
our model we decrement the effect after the initial 12-month
period, as previously described.17 Both models ascribe disutilities
to hospitalization. The MLWHF results display a much lower
health-related quality of life in both the treatment and usual care
cohorts and a reduced incremental effectiveness of treatment
compared with that seen from the EQ-5D responses. Sandhu et al.
thereby report incremental QALYs of 0.28 over a lifetime analysis,
whereas our model estimates the incremental QALYs to be 0.67
over a 10-year time horizon.
Martinson et al. have also estimated the likely cost-effectiveness
of CardioMEMS from the US perspective over a 5-year time
horizon.30 They report a base case of US$29 593 per QALY using
a payer perspective and using real-world claims data for the cost
of a HF hospitalization in the USA (US$16 770 for Medicare and
US$30 100 for private insurance) rather than an assumed cost of
US$12 832. They, like us, also did not map Minnesota scores across
to health utility, but used the directly assessed EQ-5D scores for
health-related quality of life.
The baseline mortality rate for HF in the usual care cohort
was taken from previous work by Griffiths et al. in their model
to estimate the cost-effectiveness of ivabradine as part of a sub-
mission to NICE.17 They used the CARE-HF trial31 to estimate
age-related mortality and we assumed that there were enough
similarities between that population and the target population
for CardioMEMS to use the figures as an appropriate baseline
risk of death. Although CARE-HF did not exclude NYHA class
IV patients, the study population consisted of 94% NYHA class
III patients. A total of 78% of CHAMPION patients had reduced
EF at baseline, defined as <40%, compared with the CARE-HF
inclusion criteria of <35% and a mean EF in that trial of 26%.32
Baseline risk of hospitalization for the usual care cohort was
from a meta-analysis of randomized trials of telemonitoring of
implanted devices by Klersy et al.;16 using this population probably
underestimates the risk of hospitalizations and indeed the monthly
risk of 3.5% used in the model is lower than the 5.8% calculated
from the usual care cohort in the CHAMPION trial. We believe
that this decision represents a conservative approach, and is likely
to lead to an overestimate of the cost per QALY.
Recently, the first new disease-modifying therapy for HF treat-
ment has been approved for use and is available for doctors to
prescribe in many European countries. Sacubitril–valsartan is indi-
cated in the UK for use in patients with class II–IV symptoms and
an EF of <35%. We did not attempt to model the treatment effect
of this drug within this model because at this time it is at an early
stage of adoption and it would be difficult to estimate the propor-
tion of patients in our modelled population who might already be
taking it or begin taking it within the modelled time period. Addi-
tionally, the effects in class III patients with a prior hospitalization
(the modelled population) are not clear. In the PARADIGM trial,
the primary endpoint was not significant in the subgroup of patients
in NYHA class III (HR 0.93, 95% CI 0.79–1.09) nor did the drug
reduce HF hospitalizations significantly in this subgroup (HR 1.08%,
95% CI 0.88–1.34).33 With these points in mind, we think that with
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the data available it would be difficult to model reliably how Car-
dioMEMS and sacubitril–valsartan would interact. This lack of data
is a limitation to the model at this time.
The time spent monitoring the patient also influences our esti-
mates of cost-effectiveness. Boyne et al. (TEHAF study)22 estimated
that the telemonitoring system used in their trial required 70 min a
month (an average of 2 min 20 s per day) of nurse time to triage data
from patients and to take any appropriate actions; it is important to
note that the technology used in the TEHAF study and the instruc-
tions on how to monitor patients were both very different from
the CardioMEMS™ HF system. There are very specific recom-
mendations for dealing with the data from the CardioMEMS™ HF
system and acting upon it. The selection of the time estimate from
TEHAFwas made in order to demonstrate the resource impact of a
labour-intensive approach to monitoring. More recent experience
over 18 months of using CardioMEMS in real-world clinical practice
at a single centre in the USA has indicated that HF nurses spend
on average 23 min per patient, per month. This time includes the
time spent by the nurse reviewing the tracings, calling the patient
with medication changes, ordering and checking the blood tests
required, and discussing data and actions with the physician. The
medication changes are made using an algorithm derived from the
CHAMPION study, emphasizing the judicious use of diuretics and
vasodilators, as well as maximization of guideline-based optimal
medical therapy in patients with HF and reduced EF. The nurse
spends an additional 10 min per month in documenting the medica-
tion changes in the electronic medical record. The physician spends
on average 7 min per patient per month in reviewing the data with
the nurses and setting up the treatment plan (Dr Liviu Klein, per-
sonal communication). We thought that a sensible approach to
estimating the impact of introducing this technology in terms of
human resources would be to use the data from Dr Klein’s experi-
ence as the lower bound of a situational analysis and the figure
from TEHAF as the upper bound. The ICER range of between
£22 342 and £25 464/QALY indicates that the cost-effectiveness
of the technology is affected by the time that staff spend managing
the data. However, this estimate is somewhat crude at this point in
time because the actual impact on resources remains unknown; for
this reason we did not include staff time in the base case analysis of
this model; however, when more accurate data become available it
must certainly be part of any future modelling. For instance, it is not
yet clear whether there are associated reductions in other patient
management activities (such as clinic visits or general practitioner
visits) which have not been recognized. Due to the uncertainty
we see in estimating this important aspect of the mode, we rec-
ommend that resource utilization be studied as part of any future
registry or clinical trial in the European healthcare setting.
A subgroup analysis of patients with preserved EF indicated
the possibility of greater effectiveness in this difficult to treat
population.34 When the results from this analysis were used to
inform the hospitalization rate in the model, the ICER decreased
to £18 169. However, these results were based on only 22%
of the enrolled CHAMPION population and should therefore be
interpreted with caution.
All models and modelling analyses have to make assumptions and
simplify reality in some way, which leads to limitations. The largest ..
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.. area of uncertainty in the single RCT on CardioMEMS to date is the
effect on mortality. Although the 20% beneficial effect on mortality
in the CHAMPION trial did not reach statistical significance, this
trend is included in our base case. This approach is standard
practice in economic modelling which recommends the use of
point estimates even when effect differences lack conventional
statistical significance.35,36 Readers may note that the full range
of the CI for mortality from the CHAMPION trial has not been
modelled but rather the HR is varied from the lower bound of
the CI (0.55) to 1. The values above one and the wide range
of the CIs reflect that the study was underpowered to detect
mortality. However, if we were to model a HR for mortality
above one we would be testing the assumption that the device
increases mortality and the model would produce a negative ICER,
indicating that it costs money to reduce outcomes. There is of
course no suggestion to date that the CardioMEMS system would
increase mortality. Uncertainty around the effect on mortality
using a one-way sensitivity analysis shows that the ICER could
be as high as £28 762 should the technology have no mortality
benefit. Under this scenario, the higher ICER falls within the
range of cost-effectiveness where NICE would require evidence
of considerable clinical benefit before making a recommendation
that the technology be made available to patients in England. We
have tried to make conservative choices when faced with decisions
on structure and assumptions throughout the modelling process.
These include selecting a baseline hospitalization rate which is likely
to be below that of the population of interest and only modelling
trial based utility effects to 5 years.
Cost inputs collected from other European countries show
that while cost of care varies between countries, the technol-
ogy remains cost-effective within our model, with a range of
€22 555–€23 899 per QALY. The new guidelines from the Heart
Failure Association of the European Society of Cardiology14
recommend that monitoring using the CardioMEMS system may
be considered for patients with symptomatic HF with a previous
HF hospitalization. Our model suggests that such an approach is
likely to be cost-effective in the UK, at the currently considered
threshold of value for money, and also in several other European
countries.
Conclusion
This analysis suggests that the CardioMEMS™ HF system could
provide a cost-effective means for HF physicians to manage and
treat patients outside of face-to-face clinic appointments, shifting
care from hospital/clinic to home, reducing resource-intensive
hospitalizations, and improving the quality of life of patients
suffering from HF.
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